Jyothy Labs (532926) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 consolidated revenue reached INR 704 crore (₹70,445 lacs), up 4% year-on-year, with 8% volume growth; gross margin held steady at 49.8%.

• Operating EBITDA margin declined to 16.4% from 17.5% year-on-year due to higher operating expenses and promotional activities.

• Net profit for Q3 FY25 was INR 87.4 crore (₹8,740 lacs), down from INR 90.9 crore (₹9,092 lacs) YoY; nine-month PAT up 1% to INR 294.1 crore.

• Demand environment remains subdued, with rural demand recovering gradually but not fully offsetting urban weakness.

• Financial results were reviewed and approved by the Board and auditors, with no material misstatements identified.

Financial highlights

• Q3 FY25 revenue: INR 704 crore (₹70,445 lacs, +4% YoY); nine-month revenue: INR 2,180 crore (₹2,18,002 lacs, +4% YoY).

• Gross margin: 49.8% in Q3 FY25 (flat YoY); nine-month gross margin improved to 50.4%.

• Operating EBITDA margin: 16.4% in Q3 FY25 (down 110 bps YoY); nine-month EBITDA margin up to 17.8%.

• PAT for Q3 FY25: INR 87.4 crore (₹8,740 lacs, -3.9% YoY); nine-month PAT: INR 294.1 crore (+1% YoY).

• Advertisement and sales promotion spend at 9% of sales in Q3 FY25.

Outlook and guidance

• Management remains cautious on double-digit volume growth for FY26 due to challenging market conditions but maintains ambition.

• Margin guidance remains at 16–17%, with focus on protecting Q4 margins amid volatile input prices.

• Plans for selective price hikes in personal care and continued focus on productivity and efficiency.

• Continued brand strengthening, innovation, and distribution expansion.